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Abstract
Although cancer genomes are replete with noncoding mutations, the effects of these mutations 
remain poorly characterized. Here we perform an integrative analysis of 930 tumor whole 
genomes and matched transcriptomes, identifying a network of 193 noncoding loci in which 
mutations disrupt target gene expression. These “somatic eQTLs” (expression Quantitative Trait 
Loci) are frequently mutated in specific cancer tissues, and the majority can be validated in an 
independent cohort of 3,382 tumors. Among these, we find that the effects of noncoding mutations 
on DAAM1, MTG2 and HYI transcription are recapitulated in multiple cancer cell lines, and that 
increasing DAAM1 expression leads to invasive cell migration. Collectively the noncoding loci 
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converge on a set of core pathways, permitting a classification of tumors into pathway-based 
subtypes. The somatic eQTL network is disrupted in 88% of tumors, suggesting widespread 
impact of noncoding mutations in cancer.
Human cancers are fundamentally heterogeneous, with many distinct subtypes associated 
with differences in molecular, cellular and clinical characteristics. To gain insight into this 
complexity, projects such as The Cancer Genome Atlas (TCGA) and International Cancer 
Genome Consortium (ICGC) have used massively parallel DNA sequencing to construct 
large catalogs of somatic mutations in many types of tumors1–3. Focusing initially on protein 
coding regions, several hundred genes were found to be recurrently mutated in cancer, a few 
of which are targetable therapeutically4.
Since coding regions account for less than 2% of the human genome, attention is now 
shifting to the greater number of somatic mutations in noncoding regions5. Thus far the 
clearest role for noncoding mutations in cancer has been in the promoter of the telomerase 
reverse transcriptase gene (TERT)6–8, with such mutations leading to increases in TERT 
expression levels in many types of tumors8,9. Although whole-genome sequencing (WGS) 
of tumor-normal pairs has found recurrent somatic mutations at several other noncoding loci, 
assessing the function of these mutations, if any, has been challenging6–8. In this respect, the 
task of functional interpretation is greatly aided by recent efforts of consortia such as 
ENCODE10,11 and Roadmap12,13, which have published extensive reference maps of non-
coding regions and their likely transcriptional regulatory connections to genes. Here, we 
show that such networks provide critical information for identifying noncoding mutations 
with functional impacts among the many others that may be spurious6.
RESULTS
Genome-wide identification of somatic eQTLs in cancer
To identify noncoding mutations associated with functional effects, we performed a 
systematic analysis of 930 tumors integrating whole-genome sequences, matched mRNA 
expression profiles and reference transcriptional interaction maps. Using WGS of paired 
normal and tumor tissues in 930 patients across 22 types of cancer from TCGA1 (Fig. 1a), 
we identified 3.5 × 107 sites with somatic single nucleotide variations (SNVs). We called 
these SNVs uniformly across all genomes using the MuTect suite14 according to GATK Best 
Practice recommendations15,16 and those of Melton et al.6 (Fig. 1b). Clusters of noncoding 
SNVs located within 50 base pairs of one another were grouped, defining recurrently 
mutated loci (Fig. 1c, Methods, Supplementary Fig. 1).
We then tested each locus for its association with changes in mRNA expression of target 
genes (Fig. 1d). This task made use of two additional datasets. First, enhancer-gene 
mappings in GeneHancer17 were used along with promoter-proximal regions, defined as 
sequences within 1 kb of each transcription start site (TSS), to link recurrently mutated loci 
to putative target genes considered to be under direct transcriptional control (Methods). 
Second, for the vast majority of patients with tumor genome sequences, tumor mRNA 
expression profiles were also available (Fig. 1a). From these data we developed a 
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multivariate linear regression model of the expression change of each target gene, as a 
function of the mutation status of its linked loci and co-variates including the presence of 
copy number alterations (CNAs), DNA methylation status, tissue, race, and gender (Fig. 1d, 
Methods). Conceptually this procedure is similar to identifying expression Quantitative Trait 
Loci (eQTL), in which inherited nucleotide variants are mapped to downstream functional 
changes18,19. Here, however, the variants are somatically acquired rather than inherited. 
Such “somatic eQTL analysis” simplifies the complexity and scope of eQTL mapping to a 
relatively small number of unlinked genetic variants: on average, 2.6 loci were tested per 
gene, with a standard deviation of 3.1 and a maximum number of 53 (Supplementary Fig. 
1e).
Altogether, this approach identified a cancer transcriptional network of 206 regulatory 
interactions between 193 somatic eQTLs and 196 gene expression level changes, at a false 
discovery rate (FDR) of 20% (Figs. 2a, b, Supplementary Fig. 2, somatic eQTLs at different 
FDR thresholds are provided in Supplementary Table 1 and Supplementary Note). At least 
one locus in this network was somatically mutated in 88% of cases studied (820 out of 930), 
suggesting transcriptional dysregulation through noncoding mutations is a general property 
of most tumors. Somatic eQTLs linked noncoding mutations to the expression levels of 
thirteen known tumor suppressor or oncogenes4,20,21 (Supplementary Table 1) although, 
interestingly, known cancer genes were not significantly enriched overall (Fisher’s exact test 
p-value = 0.3). We also found that 43% of somatic eQTLs disrupt or create a transcription 
factor binding motif (83 out of 193, Supplementary Table 2, Supplementary Fig. 3), 
although this percentage was very similar for recurrently mutated loci not detected as 
somatic eQTLs (40%, 2,409 out of 8,607).
Many of the identified somatic eQTLs were frequently mutated in specific cancer tissues 
(Fig. 2c, Supplementary Table 3). Beyond the promoter of TERT, which is highly mutated in 
several tissues as previously noted6–8 (Supplementary Figs. 3a, b), we found recurrently 
mutated loci associated with expression of DHX34 (mutated in 43% of diffuse large B-cell 
lymphoma), TUBBP5 (29% of lymphoma and 17% liver cancer), HYI (21% of melanoma), 
and PCDH1 (19% of acute myeloid leukemia), among others. While most of the somatic 
eQTLs were mutated in multiple tissues, 12 of the somatic eQTLs were mutated almost 
exclusively in melanoma (80% or more of the mutations occurred in melanoma). Such 
enrichment for a single tissue was not seen for any other tissue type.
Somatic eQTLs are recurrently mutated in a second cohort
To systematically validate this network, we examined an independent pan-cancer cohort 
from ICGC consisting of genome-wide somatic mutation calls for 3,382 patients2. Notably, 
we found that the majority of the somatic eQTLs identified in the original TCGA discovery 
set were recurrently mutated in the ICGC validation cohort (107 of the 193 at FDR < 20%, 
Fig. 2d). These included 10 out of the 12 melanoma eQTLs, which again were frequently 
and almost exclusively mutated in the melanoma samples in ICGC (Fisher’s exact test p-
value = 4.1 × 10−12, Supplementary Table 4). For example, a somatic eQTL associated with 
increased HYI mRNA expression level was mutated in 21% of US melanomas (TCGA) and 
18% of Australian melanomas (ICGC).
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Increasing DAAM1 expression leads to cell invasion
We next sought to examine in more detail the somatic eQTL located −191 bp upstream of 
DAAM1 (Fig. 2a, Methods), which is recurrently mutated in melanoma patients with 
metastatic disease in both cohorts (Figs. 2c, d). The DAAM1 protein forms a complex with 
Dishevelled and RhoA to recruit the actin cytoskeleton, which is thought to increase the 
motility and invasiveness of cancer cells in response to Wnt signaling22–24. Mutations at this 
somatic eQTL are associated with increased DAAM1 mRNA expression levels due 
potentially to the loss of an E2F motif and the gain of an Ets motif (Fig. 3a, NC_000014.8:g.
59655190G>A). To confirm a causal relationship between the somatic eQTL and gene 
expression level changes, wild-type and mutant DAAM1 regulatory elements were inserted 
upstream of Green Fluorescent Protein (GFP) (Fig. 3b). Analysis by flow cytometry showed 
that the mutated regulatory element leads to a significantly higher percentage of cells 
expressing GFP in melanoma, sarcoma and breast cancer cell lines (Figs. 3c, d, 
Supplementary Fig. 4). Furthermore, the GFP-expressing cells had significantly higher 
levels of GFP expression with the mutant rather than the wild type DAAM1 element in all 
four cell lines tested (Fig. 3d, Supplementary Figs. 4c, e, g).
We also explored the functional relationship between increased DAAM1 expression and cell 
motility, using an established 3D collagen hydrogel matrix model25. Genome-wide mRNA 
sequencing was performed on cells grown within low or high density collagen, mimicking 
the stiffness of normal or tumor tissues and eliciting less or more invasive phenotypes, 
respectively26,27 (Methods). In these experiments DAAM1 was one of the most up-regulated 
transcripts under invasive conditions28 (Supplementary Fig. 5). To test whether invasion was 
functionally dependent on DAAM1, we quantified cell migration behavior after DAAM1 
expression was increased artificially by exogenous overexpression (OE, Fig. 3e, 
Supplementary Fig. 6e, Methods). When cells overexpressing DAAM1 were embedded in 
the 3D collagen hydrogel, they migrated with significantly greater persistence than did wild 
type cells (p = 0.008, two-sided Mann–Whitney U test; Supplementary Fig. 6a). Cells 
overexpressing DAAM1 also invaded for longer distances than wild type cells (p = 0.01, 
two-sided Mann–Whitney U test; Figs. 3f-h), while retaining the same velocities as wild 
type cells (Supplementary Fig. 6b, c). This invasive phenotype was observed in the absence 
or presence of additional Wnt5a signaling (Supplementary Fig. 6d). These results suggest 
that increased DAAM1 expression levels allows cells to more efficiently invade the local 
microenvironment, thereby linking this noncoding mutation to DAAM1 overexpression and 
cell invasion.
Noncoding mutations dysregulating MTG2 and HYI
Beyond DAAM1, we examined two additional somatic eQTLs, one in the promoter of 
MTG2 (+19 – +33) and another in the enhancer of HYI (+95097 – +95132) (Methods). The 
first eQTL was associated with decreased MTG2 mRNA expression levels, likely due to the 
disruption of a HIF1b binding motif by the G-to-A mutation at +19 bp downstream of the 
TSS (Fig. 4a, NC_000020.10:g.60758100G>A). This somatic eQTL was present in several 
types of cancer including lung adenocarcinoma and sarcoma. Using another GFP-based 
reporter assay of promoter activity, we found that this G-to-A mutation greatly decreased 
reporter gene expression in both A549 lung epithelial carcinoma cells and U2OS bone 
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osteosarcoma cells (Fig. 4b). The second eQTL was present in 21% of melanomas (Fig. 2c) 
and was associated with increased HYI mRNA expression levels, likely due to G-to-A or 
GG-to-AA substitutions altering an Ets family binding motif (Fig. 4c, NC_000001.10:g.
43824528G>A, NC_000001.10:g.43824529G>A, or NC_000001.10:g.
43824528_43824529GG>AA). As this somatic eQTL was present in an enhancer region, we 
used a luciferase-based reporter assay where regulatory elements were cloned upstream of a 
mini-promoter and luciferase. We found that two out of the three HYI enhancer variants led 
to increased expression levels relative to wild type in both A375 melanoma cells and MDA-
MB-231 breast cancer cells (Fig. 4d).
Noncoding and coding mutations converge on pathways
Next, we investigated the relationship between the 196 genes transcriptionally regulated by 
somatic eQTLs and the 138 genes previously documented to have recurrent coding 
mutations in cancer21. This combined set of genes was analyzed by Network-Based 
Stratification29,30 (NBS; Fig. 5a), which uses a reference molecular network to implicate 
network regions associated with the genetic alterations in a tumor and groups tumors into 
subtypes based on similarity of these implicated regions. As a reference molecular network 
we used ReactomeFI31, documenting 229,300 interactions among 12,177 human gene 
products pertaining to previously reported protein-protein, transcriptional and metabolic 
interactions.
This approach identified a collection of network regions (henceforth called “pathways” for 
simplicity) that stratified tumors into a hierarchy of increasingly specific subtypes (Fig. 5b). 
At a resolution of ten subtypes, each subtype was enriched in 2-5 tumor tissues and tumors 
of each tissue could be subdivided into 1-3 subtypes (Supplementary Fig. 7). Nonetheless, 
these subtypes differed significantly in their implications for disease-free survival, beyond 
the baseline survival for each tissue (p = 3.3 × 10−6, log likelihood ratio test controlling for 
the tissue types as covariates; Fig. 5c, Supplementary Fig. 8).
Subtypes aggregating noncoding and coding mutations
Among the ten subtypes, four were of particular interest as they contained a large proportion 
of patients with noncoding mutations (Fig. 5d). The “CDKN2A-EGFR-TERT subtype” 
(Figs. 5e, f) was defined by disruption of the CDKN2A coding sequence, sometimes in 
combination with noncoding mutations to the TERT promoter, EGFR activation, or BRAF 
activation. CDKN2A encodes p14ARF, which can form a complex with Hif-1ɑ and inhibit 
HIF-1-mediated transcription of TERT32,33. These loss-of-function mutations in CDKN2A 
may release a key brake on the activity of hTERT. Separately, gain-of-function mutations in 
EGFR may lead to increased levels of mTOR phosphorylation and activation34, which can 
up-regulate telomerase activity by forming a complex with hTERT35. The synergy between 
BRAF and TERT mutations has been previously noted and attributed to modulation of TERT 
transcription through BRAF-RAS-ERK signaling36. This pathway was also linked to 
DAAM1 promoter mutations (Fig. 5d), validated previously, as Daam1 forms a complex 
with Dishevelled (Dvl3)22,23, which indirectly regulates transcription of CDKN2A and 
EGFR through inhibition of Notch137. This subtype was the most aggressive, with median 
disease free survival time at 13 months (Fig. 5c).
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A second subtype of interest, the “TERT-BRAF-IDH1 subtype” (Supplementary Fig. 9) was 
characterized by tumors with TERT noncoding mutations or amplifications, combined in 
some patients with coding alterations to functionally related genes such as BRAF and SKP2. 
Beyond the synergy between BRAF and TERT mutations as described above, Skp2 is 
essential for ubiquitination and degradation of p27Kip1 (encoded by CDKN1B)38, which 
inhibits the activity of hTERT39. Amplification of SKP2 in this pathway may thus increase 
the activity of hTERT.
A third subtype, “PIK3CA-PEX26-GATA3” (Figs. 5g, h), integrated coding alterations 
activating PIK3CA and inactivating GATA3 with noncoding alterations downregulating 
PEX26. In this pathway, members of peroxisomal biogenesis factor (Pex26 and Pex6) 
appear to indirectly interact with PIK3CA and GATA3 through the binding of SMAD family 
members (Smad3 and Smad7)40.
Finally, the fourth subtype, “APOBEC2-ARID1A-CTNNB1”, was characterized by the co-
occurrence of noncoding mutations within an enhancer of APOBEC2 and coding alterations 
in ARID1A and CTNNB1. APOBEC2 encodes a nucleic-acid editing enzyme with well-
known mutagenic effects in cancer41. Although ARID1A and CTNNB1 are also known 
cancer drivers, the connections to APOBEC are unanticipated and create a compelling 
opportunity for further study.
DISCUSSION
Relative to coding changes, interpretation of noncoding mutations poses particular 
challenges due to the very large number of events and a limited understanding of their 
functional consequences. Dealing with these challenges requires strategies to boost signal-
to-noise, which we have pursued here by integrating mutations with key structural and 
functional data on transcriptional networks. Structurally, maps of enhancer- and promoter-
gene interactions amplify signal by selecting noncoding mutations within defined regulatory 
regions of specific target genes. These mutations are then characterized functionally as 
somatic eQTLs by requiring their presence to be significantly associated with expression 
changes in tumors. The result is a global network of transcriptional regulatory interactions in 
cancer supported by multiple lines of evidence. Given that most tumors we analyzed had 
noncoding mutations affecting some part of this network, such mutations appear to represent 
a widespread feature of cancer biology.
Of the approximately two hundred noncoding mutations that have been previously identified 
as recurrent in cancer6–8, one third were also identified here as recurrently mutated loci (Fig. 
1c), including well known mutations in the promoters of PLEKHS1 and DPH3. Notably 
though, with the exception of TERT, these mutations did not associate significantly with 
mRNA expression level changes. This suggests that the effects of these mutations are 
through mechanisms outside of transcriptional regulation, or that the effects on mRNA 
expression are weaker than could be detected given our statistical power (Supplementary 
Fig. 2c). On the other hand, hundreds of somatic eQTLs were identified, all of which were 
unanticipated other than those in the promoter of TERT. Many of the affected genes are not 
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yet widely appreciated as cancer drivers, motivating further studies on the mechanistic basis 
of noncoding mutations in cancer.
Given an association between gene expression changes and a somatic mutation, it is 
important to consider whether this association reflects a causal relationship. Although it is 
tempting to assume that the occurrence of a mutation drives gene expression changes, the 
opposite could be true, where the change in gene expression levels drives the appearance of 
the mutation (e.g., by increased opening and exposure of chromatin). It is also possible that 
both effects could be due to a third causal factor. However, the three examples we tested 
experimentally do support a causal link from mutation to expression changes. These results 
include transcriptional alterations of DAAM1, impacting cell migration (Fig. 3, 
Supplementary Fig. 4); MTG2, which encodes a GTPase that regulates mitochondrial 
ribosomes42 (Figs. 4a, b); and HYI, which encodes a putative hydroxypyruvate isomerase 
and may be involved in carbohydrate transport and metabolism43 (Figs. 4c, d).
Finally, the somatic eQTL analysis introduced here contrasts with germline eQTL studies in 
several key aspects. First, in GWAS and germline eQTL studies, testing of multiple SNPs is 
complicated by the strong codependencies among neighboring SNPs at a genomic locus – 
so-called linkage disequilibrium44,45. In contrast, somatic mutations near to one another in 
the genome are not in linkage disequilibrium since these alterations, by definition, arise 
independently in each tumor. Second, population stratification caused by racial diversity has 
been a major confounder in analysis of germline variants44,45. It is less of a concern for 
somatic variants, since these are derived from comparisons between tumor and normal 
genomes from the same individual, eliminating many, if not all, effects due to ancestry. 
Nonetheless, we controlled for racial diversity and found the impact on somatic eQTL 
discovery was minimal. Given these aspects, somatic eQTL analysis may have future 
interest alongside classical eQTLs as a general mode of mapping transcriptional regulatory 
architecture.
METHODS
Calling and clustering of somatic noncoding mutations
Somatic noncoding mutations of 930 tumors were called as described in the main text. 
Clusters of noncoding mutations within d = 50 bp from each other were merged using 
BEDTools46 until no such locus was located within d bp from any other. Loci with mutations 
in k < 5 tumors were removed from further analyses. The above parameters d and k were 
chosen to aggregate mutations within short distance with a modest requirement of 
recurrence. We achieved very similar results when d was within the range of 20 to 60 
(inclusive). Whenever a subset of 930 tumors was used in subsequent analyses (Fig. 1a), this 
set was again filtered to remove those altered in fewer than k tumors within the subset. We 
also calculated a “concentration score” to penalize loci where mutations were spread over a 
large region rather than concentrated at a single base pair, as might be expected for sites 
affecting gene transcription. Within each locus, we selected the mutated position present in 
the largest number of patients. The proportion of patients affected at that position (out of all 
patients affected by mutations at that locus) was defined as the concentration score. Loci 
scoring < 35% were removed from further study. It is worth noting that the threshold of 
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concentration score is somewhat arbitrary and could lead to missing certain loci with 
multiple closely located somatic mutations. It should also be noted that by clustering 
noncoding mutations into loci, we assume that all SNVs in a locus act in a similar way. This 
assumption is consistent with the previously identified SNVs in TERT promoter. Our 
analysis does not attempt to detect loci in which different SNVs alter gene expression in 
opposite directions.
RNA-seq, CNA and DNA methylation data processing
RNA-seq, CNA (SNP 6.0) and DNA methylation (Illumina HM450) data for TCGA tumors 
were downloaded from Firehose (see URLs). The data were processed as follows. First, for 
RNA-seq the RSEM count for a gene (RNA-Seq by Expectation Maximization)47 was 
normalized by dividing by the 75th percentile of RSEM values within the tumor sample and 
multiplying by 1000, as per TCGA practice (see URLs). Genes were retained if the 
normalized RSEM > 1 in > 50% of tumors, resulting in 16,413 expressed genes. Normalized 
RSEM values were log2 transformed and z-score standardized for subsequent analyses. 
Second, for copy number alterations (CNAs) we used the output of GISTIC2, which 
indicates gene-level CNAs for all samples. The CNAs are in units of (copy number – 2), so 
that normal copy number (no amplification or deletion) has a value of 0, whereas genes with 
amplifications have positive values and genes with deletions have negative values. A gene is 
assigned the highest amplification or the lowest deletion value among the markers it covers. 
Among the 783 patients with both mRNA expression and genome sequence, 761 also had 
copy number data available. The remaining patients were assigned 0 for all CNAs. Third, 
methylation probes were mapped to the promoter regions of genes (± 1 kb from TSS), and 
each gene was assigned the mean methylation (beta) values of these probes. Among the 783 
TCGA patients with both mRNA expression and genome sequences, 605 had methylation 
data available. Methylation data for the remaining patients were imputed using mean values 
for the DNA methylation of each gene.
Linking recurrently mutated loci to transcriptional target genes
Our recurrently mutated loci were extended by 100 bp on each side when mapping to the 
promoters or enhancers. Transcriptional regulatory interactions from recurrently mutated 
loci to target genes were defined whenever a locus had 50% of its sequence overlap with 
either the promoter region of a gene (± 1 kb from its TSS) or a gene enhancer region defined 
by GeneHancer17. In case an enhancer is shorter than a locus, the mapping was performed 
when 50% of the enhancer sequence overlaps with the locus.
Somatic eQTL analysis using multivariate linear regression
For each gene target linked to recurrently mutated loci, we fit a regression model of the 
normalized gene expression level e as a function of l, the alteration status of its recurrently 
mutated loci (1 = mutated; 0 = wt), controlling for the impact of CNA status c (0 = wt; 
positive values for amplifications; negative values for deletions), DNA methylation m (mean 
beta-values), 21 tumor tissues t (binary variables), 3 races r (binary variables: Asian; Black 
or African American; White), gender g (1 = Female; 0 = male) and 20 hidden factors h (real 
values) as covariates:
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e = β0 + β1l + β2c + β3m + β4t + β5r + β6g + β7h (Eq. 1)
The hidden factors h were identified using probabilistic estimation of expression residuals 
(PEER)48,49, while accounting for the effect of known covariates t, r and g. The number of 
hidden factors was determined by the posterior variance of the factor weights, as previously 
recommended49. The parameters β were estimated from data from 783 tumors with matched 
RNA-seq and WGS data. Somatic eQTLs were identified as follows. First, for each gene, we 
selected features by adding an L1-norm to the objective function based on least squared 
error between true and predicted gene expression level.
e − e 2 + λ β 1 (Eq. 2)
The sparsity parameter λ was optimized by cross validation. For genes in which the L1-
norm resulted in β1 = 0 for all loci, we decreased λ to include at least one locus. Second, to 
assess whether mutation status of any locus contributed significantly to gene expression, the 
accuracy of the complete model was compared to that of a simple model under null 
hypothesis of no genetic associations (i.e., β1 = 0 for all loci). The F-test p-value between 
the two nested models was used as the test statistic. Third, having derived an F-test p-value 
for each gene, q-values were calculated using the Storey approach50 with a threshold of FDR 
≤ 20%. And finally, for each gene that passed the selection, this threshold was mapped back 
to the equivalent F-test p-value of each locus. Loci with F-test p-value below or equal to this 
threshold were included in the final list and defined as somatic eQTLs.
We elected to perform one test per gene for three reasons. First, in GWAS and typical 
(germline) eQTL studies, linkage disequilibrium complicates the simultaneous testing of 
multiple SNPs in a single model, because these SNPs are usually codependent. Unlike 
inherited SNPs, somatic mutations observed in a tumor population are not in linkage 
disequilibrium no matter how closely they are located. Therefore, a simple F-test, which 
assumes independent influences of multiple factors, is sufficient to simultaneously test 
whether any loci are associated with gene expression. Second, for each gene, all eQTLs 
share the same set of covariates along with the associated phenotype of mRNA expression 
level. If multiple eQTLs are associated with gene expression levels, they can be covariates of 
one another. It is then convenient to fit them all in a single model and enjoy the benefit of 
gene-based approaches such as feature selection by L1 regularization. Third, there is 
precedent in the literature to fit gene-level models in eQTL studies51,52.
Power analysis
Statistical power depends on various parameters, including the number of samples, the 
eQTL effect size, the noise, and the significance threshold. Instead of a simulation based on 
a model of noise, we evaluated statistical power using the actual data. All locus-gene pairs 
were plotted in Supplementary Fig. 2c, evaluated by the number of patients with mutations 
(x-axis) versus the change in gene expression given the mutation (y-axis; defined by 
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W = CoefficientResidual standard deviation ; one unit of W represents one standard deviation of change in 
residual gene expression). Power was defined as 1 – P(Type II error) at a significance level 
of P(Type I error) = 0.0085, which is approximately at 20% FDR. We calculated power 
using the “pwr.f2.test” function in R, where the f 2 effect size was calculated based on the 
proportion of explained variance by two nested models ( f 2 =
Ralternative
2 − Rnull
2
1 − Ralternative
2 ). Our 
somatic eQTL analysis has 50% power to detect a somatic eQTL with 5 mutations if W > 
1.2 or with 10 mutations if W > 0.9.
Independent validation of recurrence
To validate the recurrence of mutations in the identified somatic eQTLs, we downloaded 
simple somatic mutations (substitutions) called from the WGS of n = 3,382 publicly 
available non-US donors from the ICGC2. For each eQTL, the number of mutated patients k 
was used as the test statistic. To determine whether k was greater than expected due to the 
background mutation rate (BMR), we developed an approach for estimating BMR that was 
conceptually similar to MutSigCV53. First, a large pool of 20,000 candidate background 
sequences was created by randomly reassigning (without replacement) the location of the 
eQTL to the same type of noncoding genomic regions (promoters or putative enhancers17), 
while retaining the eQTL’s length. Each of these 20,000 sequences was placed in a three-
dimensional feature space taking into account nucleotide content, DNA replication timing 
and gene expression. Nucleotide content was represented as the percentages of all possible 
mono- (A/T vs. C/G), di- (e.g., AA, AC and AG) and tri-nucleotides (e.g., AAA, AAC and 
AAG), encoded as a 44-dimensional vector. This information was then compressed into a 
single feature representing nucleotide content, using the Pearson’s correlation between the 
vector of the candidate sequence and the vector of the original eQTL. DNA replication 
timing was obtained from ENCODE via the UCSC Genome Browser54. To create a single 
replication timing feature, we used the average wavelet-smoothed signal from the following 
14 cell lines: BJ, GM06990, GM12801, GM12812, GM12813, GM12878, HeLa-S3, 
HepG2, HUVEC, IMR-90, K-562, MCF-7, NHEK and SK-N-SH, according to the method 
of Melton and colleagues6. For gene expression, the median expression value of the nearest 
gene (log2 transformed RNA-seq data, 783 TCGA patients) was used as a feature. The above 
three features were z-score standardized. Within this feature space, the top 5% (1,000 out of 
20,000) background sequences with the smallest Euclidean distance to the eQTL of interest 
were selected. For each patient, a patient-specific BMR was estimated as the number of 
sequences with at least one mutation in that patient out of the 1,000 selected sequences. 
Finally, we estimated the probability of having observed k or more mutations in n patients in 
the eQTL of interest using a Poisson binomial model:
P K ≥ k = ∑l = kn ∑A ∈ Fl∏i ∈ A pi∏ j ∈ Ac (1 − p j) (Eq. 3)
where Fl is the set of all subsets of k integers that can be selected from {1, 2, …, n}, pi or pj 
is the probability that patient i or patient j is mutated, A is a set of k integers that can be 
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selected from {1, 2, …, n} and Ac is the complement of A. In practice, we used an 
approximation for the Poisson binomial in the poibin python package (see URLs).
Transcription factor binding motif analysis
Each reference and somatically altered nucleotide site, along with ± 7 bp flanking sequence, 
was analyzed using HOMER55 (see URLs). HOMER searches for matches within a library 
of 319 vertebrate motifs (position weight matrices). Specifically, we ran the “findMotifs.pl” 
program with default parameters to find motifs from FASTA files. The reference and altered 
sequences were used as the background for each other to control the nucleotide context. The 
command line is: findMotifs.pl seqList_mappable_alt.fa fasta log/ -fastaBg 
seqList_mappable_ref.fa -p 16 -find ~/soft/homer/data/knownTFs/vertebrates/known.motifs.
The list of somatic eQTLs disrupt or create transcription factor binding motifs in four or 
more patients were reported in Supplementary Table 2.
Prioritizing somatic eQTLs for subsequent functional validation
The three somatic eQTLs selected for functional studies (DAAM1, HYI1 and MTG2) were 
chosen based on the specific biological interest of the authors and several rules-of-thumb:
1. The somatic eQTL alters a known transcription factor binding motif in many 
patients;
2. The somatic eQTL falls in open chromatin in previously mapped cell lines and 
conditions (e.g., in regions with markers such as H3K27ac and H3K4me1)11;
3. The affected target gene has high endogenous mRNA expression levels in cell 
lines56 that match where the somatic eQTL was detected; and
4. The somatic eQTL is not present in a region with repetitive DNA.
Note that none of this information was used to filter loci prior to somatic eQTL analysis, as 
it is not complete, conclusive or cancer-specific.
Generation of reporter plasmids
To examine the effect of the DAAM1 somatic eQTL on gene expression levels, the wild type 
and mutant regulatory regions, from −233 bp to +148 bp relative to the TSS, including the 
somatic eQTL at −202 – −191 bp, were synthesized and cloned upstream of GFP (Fig. 3b). 
For MTG2, the cloned region spanned −200 bp to +200 bp relative to the TSS, including the 
somatic eQTL at +19 – +33 bp.
For the somatic eQTL located in the HYI enhancer, the region corresponding to +94931 bp 
to +95332 bp relative to the TSS, including the somatic eQTL at +95097 – +95132 bp, was 
cloned into the firefly luciferase reporter plasmid pGL4.23 (Promega). The mutations were 
generated using the Q5 Site-Directed Mutagenesis Kit (New England BioLabs). All inserts 
for the GFP and luciferase reporter plasmids were confirmed to match the human reference 
genome hg19 by Sanger sequencing.
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Promoter and enhancer activity assays
Cell lines used to evaluate of promoter activity were plated in 6-well dishes at 300,000 cells 
per well, three replicates per group. The next day, plasmid DNA (1 μg) was transfected using 
Lipofectamine 3000 (ThermoFisher). Forty-eight hours after transfection, cells were 
harvested and suspended in ice cold PBS with 1% fetal bovine serum. GFP expression was 
measured by flow cytometry on a FACSCalibur or FACSCanto (BD Biosciences). Flow 
cytometry data were analyzed with FlowJo v10 (BD Biosciences). Cells with typical forward 
(size) and side (granularity) scatter properties were further analyzed for GFP expression. As 
a negative control, cells were transfected with an empty lentiGuide-Puro plasmid (Addgene) 
for the DAAM1 experiments (Figs. 3c, d; Supplementary Fig. 4) or a promoter-less GFP 
plasmid (pRMT-tGFP, Origene) for the MTG2 experiments (Fig. 4b). As a positive control 
for all GFP experiments, we used a plasmid with the cytomegalovirus promoter upstream of 
GFP. All flow cytometry experiments were performed at least three times. Early pilot 
experiments were often performed on single or duplicate samples with then the final 
triplicate version often performed at least twice.
To evaluate the activity of the enhancer region of HYI, A375 and MDA-MB-231 cells were 
plated in white, opaque, 96-well plates at 10,000 cells per well, four replicates per group. 
Cells were transfected 24 hours later using lipofectamine 3000 with 33 ng of total DNA: 
27.5 ng of the firefly pGL4.23 constructs and 5.5 ng of control Renilla pGL4.75 (Promega) 
plasmid. Firefly and Renilla activity were measured 48 hours after transfection using the 
Dual-Glo Luciferase Assay System (Promega) as per the manufacturer’s instructions. 
Luciferase values were collected on a BioTek Synergy HT, and data collected via software 
Gen5 2.01.14. To calculate relative luciferase values, background signal was first subtracted 
from each channel. Then firefly luminescence was divided by Renilla luminescence. The 
average value for the wildtype enhancer was set to 1, and the mutated samples were 
evaluated in comparison to this control. Experiments in both cell lines were performed three 
times, with each experiment consisting of samples in quadruplicate.
DAAM1 overexpression
Wild type MDA-MB-231 breast cancer cells were transfected with a plasmid encoding the 
full DAAM1 gene cDNA (Origene catalog number: RC217675). Cells were then selected 
using G418 (500 μg/mL) for 7 days to ensure stable expression of the DAAM1 construct. 
DAAM1-overexpression was verified by extracting total protein and quantitating using the 
Wes electropherogram (Proteinsimple) with anti-DAAM1 antibody (clone WW-3, cat# 
sc-100942, lot# B1815, Santa Cruz, 1:250 dilution) and anti-tubulin antibody (clone YL1/2, 
cat# MAB1864, lot# 2886723, Millipore, 1:250 dilution). DAAM1 expression was 5.5 fold 
greater in cells with DAAM1-overexpression construct relative to wild type (Supplementary 
Fig. 6e).
3D collagen cell migration assay
Collagen matrices were prepared by mixing cells suspended in culture medium and 10× 
reconstitution buffer, one-to-one with soluble rat tail type I collagen in acetic acid 
(Corning)25. Sodium hydroxide was used to normalize pH (pH 7.0, 10 – 20 μL 1M NaOH), 
and the mixture was placed in 48-well culture plates for polymerization at 37°C. Final gel 
Zhang et al. Page 12
Nat Genet. Author manuscript; available in PMC 2018 October 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
volumes were approximately 200 μL with final collagen concentration set to 2.5 mg/mL. 
The polymerized cell-laden hydrogels were incubated for 24 hours under a standard cell 
culture environment before imaging. Gels were then transferred to a microscope stage-top 
incubator, and cells were imaged at low magnification (10×) every 2 minutes for 48 hours. 
Coordinates of the cell location at each time frame were determined using image recognition 
software (Metamorph/Metavue, Molecular Devices). Tracking data were processed to 
calculate cell speed using an extension of previously published scripts57. Cell migration 
assays (Fig. 3f-h) were performed two times and both attempts showed the same trend.
RNA sequencing from cells in 3D culture
In Supplementary Figure 5, cell migration assays were performed using wild type MDA-
MB-231 breast cancer cells and HT-1080 fibrosarcoma cells. 3D collagen I gels were seeded 
in 3 independent experiments and harvested after 24 hours of culture for RNA extraction and 
directly homogenized in Trizol reagent (Thermofisher). Total RNA was purified using High 
Pure RNA Isolation Kit (ROCHE) and the integrity of the sample verified using RNA 
Analysis ScreenTape (Agilent Technologies). Total RNA samples were sequenced using the 
TruSeq Stranded mRNA Sample Prep Kit (Illumina) and the Illumina MiSeq platform at a 
depth of > 25 million reads per sample. Paired-end reads were aligned to the hg19 UCSC 
human genome reference using Bowtie258 and streamed to eXpress59 for transcript 
abundance quantification.
Tumor genetic profiles integrating noncoding and coding alterations
Integrated genetic alteration profiles were constructed for the 810 tumors with WGS, WES 
and CNA data (Fig. 1a) as follows. Known oncogenes or tumor suppressors21 were 
combined with the set of target genes of eQTLs identified by the somatic eQTL analysis (see 
above); each of these genes was then classified as wild type (0) or altered (1) in each tumor, 
constituting its tumor genetic profile. In this profile, an alteration was defined as follows: 
Most oncogenes (e.g., EGFR) were considered altered (activated) if impacted by a missense 
mutation, in-frame indel, or copy-number amplification. For oncogenes typically altered 
only by amplification21 (CCND1, MDM2, MDM4, MYC, MYCL, MYCN, NCOA3 and 
SKP2), only copy number amplifications were considered as alterations and not SNVs or 
indels. Tumor suppressors (e.g., CDKN2A) were considered altered (inactivated) if there 
was any type of non-silent mutation or a copy number deletion. For each target gene, we 
defined a dominant direction of regulation d ∊ {+1, −1} as the sign of the coefficient (β1 in 
Eq. 1) of its most significantly associated eQTL. Noncoding mutations in eQTLs that lead to 
a transcriptional change in the dominant direction were considered alterations of such genes. 
For TERT, copy number amplifications in the coding region was also considered as 
alterations, since both promoter mutations and gene amplifications have been associated 
with growth advantage of tumor cells and poor prognosis of patients60,61.
Network-Based Stratification (NBS) to identify tumor subtypes
Network propagation29 was used to compute the pairwise similarities among tumor genetic 
alteration profiles (see above) within the Reactome functional interaction network 
(ReactomeFI)31. Each tumor genetic profile was propagated across this network based on a 
random walk model (equivalent to heat diffusion) with a restart probability of 0.5. After 
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convergence, the score of each gene (temperature) represents its network proximity to 
genetic alterations. The top 70 principal components of these scores, representing the 
tumor’s network-transformed profile (Fig. 5a), were analyzed using the 
sklearn.cluster.SpectralClustering package62 (affinity = k-Nearest-Neighbors, assign-labels = 
discretize, n_clusters = [2..10]). This method first constructs a similarity graph on all pairs 
of tumors, where each tumor is connected to the k others with shortest Euclidean distance. 
We chose k = 170, which ensures the similarity graph to be connected, as previously 
recommended62. Next this graph is analyzed to partition tumors into subtypes at different 
resolutions (number of subtypes n = [2..10]). Following spectral clustering, each set of n 
(parent) subtypes was compared to the n + 1 (child) subtypes to track the similarity of tumor 
assignments (Fig. 5b). An arrow is drawn from a parent to child subtype if they share ≥ 18 
tumors.
Characterizing tumor subtypes with signature genes and subnetworks
For each subtype, we defined a set of “signature genes” as those that had higher network-
transformed scores in that subtype than others (t-test, Benjamini Hochberg FDR < 0.1) and, 
among these, were more frequently altered in that subtype (Fisher Exact Test, FDR < 0.05, 
Figs. 5b-e). To identify subnetworks, this set was expanded to include “intermediate genes” 
with relatively high network-transformed score (t-test, FDR < 0.05) that lie on the shortest 
paths between each pair of signature genes. The union of the signature and intermediate 
genes was used to induce a subnetwork within ReactomeFI31, referenced in the main text as 
the corresponding “pathway” impacted in that subtype (Figs. 5d). An additional filter was 
applied in Fig. 5e and Supplementary Fig. 9a, where we only visualized the signature genes 
with 10 or more mutations and the shortest paths among them with at most one intermediate 
gene. All networks were visualized in Cytoscape63.
Survival analysis
We used the “coxph” package in the R statistics software to fit Cox proportional hazard 
models64. P-values were calculated by log likelihood ratio test. To evaluate whether the 
subtype classifications provide additional prognostic power beyond the baseline survival 
expectancy due to cancer tissue, we compared the likelihood for the complete model, 
including NBS-derived molecular subtypes s and cancer tissues c as covariates, against that 
of a null model that includes cancer tissues c only:
Complete model: λ t s, c = λ0 t exp(β0 + β1s + β2c) (Eq. 4)
Null model: λ t s, c = λ0 t exp(β0 + β2c) (Eq. 5)
where λ0 t  is the baseline hazard function. Then a log-likelihood ratio statistic was defined 
as:
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D = − 2ln likelihood for null modellikelihood for complete model (Eq. 6)
Finally, a chi-squared test p-value was calculated based on D with the number of degrees of 
freedom equal to the number of NBS-derived molecular subtypes.
Data availability
Somatic mutations of 930 tumors are publicly available (see URLs). RNA-seq data is 
accessible through the GEO Series accession number GSE101209.
Code availability
Custom code for annotating mutations, somatic eQTL analysis, validation of recurrence, 
motif analysis and Network-Based Stratificaion are available through GitHub (see URLs).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutation calling and somatic eQTL analysis
(a) Types of data and numbers of tumors used in this study. (b) Number of mutations called 
per tumor. Boxplots show the distribution of this number within tumors of each tissue type 
(center line, median; upper and lower hinges, first and third quartiles; whiskers, highest and 
lowest values within 1.5 times the interquartile range outside hinges; dots, outliers beyond 
1.5 times interquartile range). The number of tumors of each type (sample size) is shown on 
the right panel. (c) Clustering of somatic noncoding mutations resulting in identification of 
recurrently mutated loci. (d) Workflow of somatic eQTL analysis.
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Figure 2. Effect size and recurrence of somatic eQTLs
(a) Volcano plot of associations between somatic eQTLs and the expression levels changes 
of their target genes, evaluated by significance (y-axis, F-test p-value, n = 783 tumors) 
versus effect size (x-axis). One unit on the x-axis represents one standard deviation of 
change in gene expression. FDR is calculated using the Storey approach50. Selected somatic 
eQTLS are labeled by coordinates in base pairs relative to the TSS of the target gene. (b) 
Ideogram of the 193 significant somaitc eQTLs at FDR < 20%. (c) Heatmap showing the 
percentage of patients in various cancer tissues with alterations in each somatic eQTL. 
Somatic eQTLs and cancer tissues with ≥ 15% mutation rates are shown. (d) Validation of 
somatic eQTL recurrence in a pan-cancer cohort from ICGC. The quantile–quantile plot 
shows the observed empirical p-values of mutation recurrence (n = 3,382 tumors) compared 
to the random expectation for the 193 somatic eQTLs. FDR is calculated using the 
Benjamini-Hochberg approach.
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Figure 3. Functional validation of the mutated DAAM1 regulatory element
(a) A somatic eQTL in the DAAM1 promoter region is associated with increased mRNA 
expression levels. (b) Schematic of wild type and mutant GFP reporter constructs along with 
the Sanger sequencing traces confirming the sequence of the key nucleotide. (c) Flow 
cytometry analysis of A375 human melanoma cells 48 hours after transient transfection. The 
polygon delineated by black lines shows the gated region used to define GFP+ cells. (d) Bar 
graphs (average ± standard deviation across 3 cell culture replicates; p-values from two-
tailed t-tests) showing the percentage of GFP+ cells and the median fluorescence intensity of 
the GFP+ cells. Individual data points are in Supplementary Table 5. (e) Protein 
electropherogram analysis of wild type and DAAM1 overexpressing MDA-MB-231 cells 
using the antibodies against DAAM1 and tubulin. The complete electropherogram is in 
Supplementary Fig. 6e. The image is representative of two independent cell culture 
experiments. (f, g) Sample trajectories of (f) wild type and (g) DAAM1-overexpressing cells 
embedded in 2.5 mg/mL 3D collagen hydrogels. (h) Total invasion distance travelled by 
individual cells (p-value from two-tailed Mann–Whitney U test; 95% confidence intervals of 
mean are (32.3 μm, 48.2 μm) and (47.6 μm, 67.0 μm) for wild type and DAAM1-
overexpressing cells, respectively). Imaging and quantitation was performed on 74 and 83 
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cells in the wild type and DAAM1-overexpression groups, respectively. Box-plot elements 
are defined as Fig. 1b.
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Figure 4. Additional case studies
(a) The somatic eQTL associated with downregulation of MTG2 is located in its 5′ UTR 
and frequently alters a potential HIF-1b binding motif. (b) Flow cytometry analysis of A549 
lung epithelial carcinoma cells and U2OS bone osteosarcoma cells 48 hours after transient 
transfection with MTG2 GFP reporter constructs. Bar graphs (mean ± standard deviation 
across three cell culture replicates; p-values from two-tailed t-tests) showing the percentage 
of GFP+ cells and the median fluorescence intensity of GFP+ events. (c) The somatic eQTL 
associated with upregulation of HYI is located 95 kb downstream of the TSS and frequently 
alters a potential Ets family binding motif. (d) Luciferase assay results (mean ± standard 
deviation across four cell culture replicates; p-values from two-tailed t-tests) for the HYI 
somatic eQTLs 48 hours after transient transfection in A375 melanoma cells and MDA-
MB-231 breast cancer cells. Individual data points are available in Supplementary Tables 5 
and 6.
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Figure 5. Identification of molecular networks and associated tumor subtypes incorporating 
noncoding mutations
(a) Workflow of Network-Based Stratification. (b) Resulting hierarchy of subtypes, at 
increasing resolution from 2-10 subtypes. (c) Disease-free survival probabilities (y-axis) are 
plotted against time after diagnosis in months (x-axis) for each of the identified cancer 
subtypes (colors). Patients with censored survival data are indicated by a “+” at the 
censoring time (last follow-up). (d) Signature genes are shown for each subtype with a large 
proportion of patients with noncoding mutations (x-axis), ordered by the percent of patients 
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with alterations (y-axis). (e, g) Pathways characterizing (e) CDKN2A-EGFR-TERT or (g) 
PIK3CA-PEX26-GATA3 subtypes, defined as subnetwork regions extracted from 
ReactomeFI by Network-Based Stratification. (f, h) Mutation matrix of the (f) CDKN2A-
EGFR-TERT or (h) PIK3CA-PEX26-GATA3 pathway subtypes showing individual tumors 
(columns, ordered by cancer tissues) with indicated types of mutations on signature genes 
for that subtype (rows).
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